AIM Vaccine Co (HKSE:06660) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:06660 AIM Vaccine Co Ltd HKSE:06660
61 GF Score
Price HK$1.70
GF Value HK$4.08
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is AIM Vaccine Co Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

HKSE:06660
61GF Score
AIM Vaccine Co Ltd HKSE:06660
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is AIM Vaccine Co (HKSE:06660) Overvalued in 2026?

Based on GuruFocus' analysis, AIM Vaccine Co stock appears to be undervalued. The current stock price of HK$1.70 is trading 58.5% below its estimated GF Value™ of HK$4.08. GuruFocus considers AIM Vaccine Co to be Possible Value Trap.

Key valuation signals for HKSE:06660:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: HK$4.08 vs. price of HK$1.70 (58.5% below fair value)
  • GF Score™: 61/100 with 7 warning signs

No single metric tells the full story. See the HKSE:06660 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AIM Vaccine Co Business Description

Address 2 Ronghua South Road, 26th Floor, Building T6, Han’s Plaza, Economic Technological Development Area, Beijing, CHN
AIM Vaccine Co Ltd is a China-based full-chain vaccine company engaged in the research and development, manufacturing, and commercialization of vaccine products. The company's commercialized products include recombinant HBV vaccines, freeze-dried human rabies vaccines, inactivated HAV vaccines, Group A, C, Y, and W135 meningococcal polysaccharide vaccines, bivalent inactivated HFRS vaccines, and mumps vaccines. The company generates the majority of its revenue from the PRC.
61GF Score

Get the complete analysis for HKSE:06660

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$1.70
Price
HK$4.08
GF Value